BioSpace News Archive

CereVasc, Inc. announced that data from clinical studies examining the use of its eShunt System to treat elderly patients with normal pressure hydrocephalus and patients with communicating hydrocephalus following treatment for a ruptured cerebral aneurysm, was recently presented at the Congress of Neurological Surgeons (CNS) Annual Meeting in Washington, DC.

Azenta, Inc. announced that Herman Cueto will join Azenta as Executive Vice President and Chief Financial Officer, effective October 16.

Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced that Australia’s Therapeutic Goods Administration (TGA) has granted approval for Vafseo® (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of anemia associated with chronic kidney disease (CKD) in adults on chronic maintenance dialysis.

Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present in a fireside chat at Chardan’s 7th Annual Genetic Medicines Conference in New York, on Tuesday, October 3, 2023 at 2:00 p.m. ET.

Melt Pharmaceuticals, Inc. today announced it recently entered into an exclusive development and license agreement with Catalent, the global leader in enabling the development and supply of better treatments across multiple modalities.

Panbela today announced an Issue Notification for the Chinese patent 201980010826.7 titled “METHODS FOR PRODUCING (6S,15S)-3,8,13,18- TETRAAZAICOSANE-6,15-DIOL”.

Today COTA announced Vista, a large-scale automated electronic health record (EHR) dataset to accelerate cancer research and the deployment of trusted generative AI in cancer care.

NTT Research, Inc. , a division of NTT (TYO:9432), today announced that it has named Timothée Leleu as Senior Research Scientist and a Group Head in the Physics & Informatics (PHI) Lab.

Elpiscience Biopharmaceuticals announced today that the first patient has been dosed in a Phase 1 clinical trial of its anti-LILRB2 monoclonal antibody ES009 in Australia.

Biomerica, Inc. announced that the Dubai government has officially approved insurance reimbursement for the EZ Detect colorectal disease at-home screening test, which is designed to detect an early warning sign of colorectal cancer and other colorectal diseases.